theMednetRegister

Metastatic HR+ Breast Cancer   

Questions discussed in this category

How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
Should these patients have a different threshold for utilizing a CDK4/6 inhibitor in the front line metastatic or as part of adjuvant therapy, or SERD...
1 Answer available


Papers discussed in this category

Breast cancer research and treatment, 2020 Aug 10
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
JCO precision oncology, 2022 Mar
Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 19
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.

Related Topics

Copyright © 2024 theMednet
All Rights Reserved.